Short stature syndromes

Growth Disorders, Second Edition

Volumn , Issue , 2007, Pages 259-280

  Mortier, Geert R ^a   Graham, John M ^b   Rimoin, David L ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84994238438     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (152)

1. Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107: 317–29.
2. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976; 51: 170–9.
3. Freeman JV, Cole TJ, Chinn S, et al. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995; 73: 17–24.
4. Gorlin RJ, Cohen MM, Hennekam RCM (eds). Syndromes of the Head and Neck. Oxford: University Press, 2001.
5. Cooley WC, Graham JM. Down syndrome – an update and review for the primary pediatrician. Clin Pediatr 1991; 30: 233–53.
6. Clementi M, Calzolari E, Turolla L, et al. Neonatal growth patterns in a population of consecutively born Down syndrome children. Am J Med Genet 1990; 7(Suppl): 71–4.
7. Cronk C, Crocker AC, Pueschel SM, et al. Growth charts for children with Down syndrome: 1 month to 18 years of age. Pediatrics 1988; 81: 102–10.
8. Toledo C, Alembik Y, Aguirre JA, Stoll C. Growth curves of children with Down syndrome. Ann Genet 1999; 42: 81–90.
9. Baty BJ, Blackburn BL, Carey JC. Natural history of trisomy 18 and trisomy 13: Growth, physical assessment, medical histories, survival, and recurrence risk. Am J Med Genet 1994; 49: 175–88.
10. Tolmie JL. Down syndrome and other autosomal trisomies. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR (eds). Emery and Rimoin’s Principles and Practice of Medical Genetics. London: Churchill Livingstone, 2002: 1129–83.
11. Allanson JE, Graham GE. Sex chromosome abnormalities. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR, eds. Emery and Rimoin’s Principles and Practice of Medical Genetics. London: Churchill Livingstone, 2002: 1184–201.
12. Sybert VP. Turner syndrome. In: Cassidy SB, Allanson JE, eds. Management of Genetic Syndromes. New York: Wiley- Liss, 2001: 459–84.
13. Schinzel A, ed. Catalogue of Unbalanced Chromosome Aberrations in Man. Berlin: De Gruyter, 2001.
14. Zollino M, Lecce R, Fischetto R, et al. Mapping the Wolf–Hirschhorn syndrome phenotype outside the currently accepted WHS critical region and defining a new critical region, WHSCR-2. Am J Hum Genet 2003; 72: 590–7.
15. Zollino M, Di Stefano C, Zampino G, et al. Genotype–phenotype correlations and clinical diagnostic criteria in Wolf–Hirschhorn syndrome. Am J Med Genet 2000; 94: 254–61.
16. Wieczorek D, Krause M, Majewski F, et al. Effect of the size of the deletion and clinical manifestations in Hirschhorn syndrome: analysis of 13 patients with a de novo deletion. Eur J Hum Genet 2000; 8: 519–26.
17. Van Buggenhout G, Melotte C, Dutta B, et al. Mild Wolf–Hirschhorn syndrome: micro-array CGH analysis of atypical 4p16.3 deletions enables refinement of the genotype–phenotype map. J Med Genet 2004; 41: 691–8.
18. Zhang A, Zheng C, Hou M, et al. Deletion of the telomerase reverse transcriptase gene and haploinsufficiency of telomere maintenance in Cri du chat syndrome. Am J Hum Genet 2003; 72: 940–8.
19. Mainardi PC, Perfumo C, Cali A, et al. Clinical and molecular characterization of 80 patients with 5p deletion: genotype–phenotype correlation. J Med Genet 2001; 38: 151–8.
20. Marinescu RC, Mainardi PC, Collins MR, et al. Growth charts for cri-du-chat syndrome: an international collaborative study. Am J Med Genet 2000; 94: 153–62.
21. Gul D, Ogur G, Tunca Y, Ozcan O. Third case of WAGR syndrome with severe obesity and constitutional deletion of chromosome (11)(p12p14). Am J Med Genet 2002; 107: 70–1.
22. Spinner NB, Emanuel BS. Deletions and other structural abnormalities of the autosomes. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR, eds. Emery and Rimoin’s Principles and Practice of Medical Genetics. London: Churchill Livingstone, 2002: 1202–36.
23. Cassidy SB. Prader–Willi syndrome. In: Cassidy SB, Allanson JE, eds. Management of Genetic Syndromes. New York: Wiley-Liss, 2001: 301–22.
24. Eiholzer U, Whitman BY. A comprehensive team approach to the management of patients with Prader–Willi syndrome. J Pediatr Endocrinol Metab 2004: 17: 1153–75.
25. Allen DB, Carrel AL. Growth hormone therapy for Prader–Willi syndrome: a critical appraisal. J Pediatr Endocrinol Metab 2004: 17(Suppl 4): 1297–306.
26. Dattani M, Preece M. Growth hormone deficiency and related disorders: insights into causation, diagnosis, and treatment. Lancet 2004: 363: 1977–87.
27. Mortier GR. The diagnosis of skeletal dysplasias: a multidisciplinary approach. Eur J Radiol 2001: 40: 161–7.
28. Grier RE, Farrington FH, Kendig R, Mamunes P. Autosomal dominant inheritance of the Aarskog syndrome. Am J Med Genet 1983: 15: 39–46.
29. van de Vooren MJ, Niermeijer MF, Hoogeboom JM. The Aarskog syndrome in a large family suggestive for autosomal dominant inheritance. Clin Genet 1983: 24: 439–45.
30. Pasteris NG, Cadle A, Logie LJ, et al. Isolation and characterization of the faciogenital dysplasia (Aarskog–Scott syndrome) gene: a putative Rho/Rac guanine nucleotide exchange factor. Cell 1994: 79: 669–78.
31. Porteous MEM, Goudie DR. Aarskog syndrome. In: Donnai D, Winter RM, eds. Congenital Malformation Syndromes. London: Chapman & Hall Medical, 1995: 106–11.
32. Orrico A, Galli L, Cavaliere ML, et al. Phenotypic and molecular characterization of the Aarskog–Scott syndrome: a survey of the clinical variability in light of FGD1 mutation analysis in 46 patients. Eur J Hum Genet 2004; 12: 16–23.
33. Afzal AR, Rajab A, Fenske C, et al. Autosomal recessive Robinow syndrome is allelic to dominant brachydactyly type B and caused by loss of function mutations in ROR2. Nat Genet 2000; 25: 419–22.
34. van Bokhoven H, Celli J, Kayserili H, et al. Mutation of the gene encoding the ROR2 tyrosine kinase causes autosomal recessive Robinow syndrome. Nat Genet 2000; 25: 423–6.
35. Patton MA, Afzal AR. Robinow syndrome. J Med Genet 2002; 39: 305–10.
36. Weinstein LS, Gejman PV, Friedman E, et al. Mutations of the Gs _-subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. Proc Natl Acad Sci USA 1990; 87: 8287–90.
37. Spiegel AM, Weinstein LS. Inherited diseases involving G proteins and G protein-coupled receptors. Annu Rev Med 2004; 55: 27–39.
38. Miric A, Vechio JD, Levine MA. Heterogeneous mutations in the gene encoding the _-subunit of the stimulatory G protein of adenyl cyclase in Albright hereditary osteodystrophy. J Clin Endocrinol Metab USA 1993; 76: 1560–8.
39. Germain-Lee EL, Ding C-L, Deng Z, et al. Paternal imprinting of G_s in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. Biochem Biophys Res Commun 2002; 296: 67–72.
40. Weinstein LS, Liu J, Sakamoto A, et al. Minireview: GNAS: normal and abnormal functions. Endocrinology 2004; 145: 5459–64.
41. Fitch N. Albright hereditary osteodystrophy. A review. Am J Med Genet 1982; 11: 11–29.
42. Wilson LC, Leverton K, Oude Luttikhuis ME, et al. Brachydactyly and mental retardation: an Albright hereditary osteodystrophy-like syndrome localized to 2q37. Am J Hum Genet 1995; 56: 400–7.
43. Wilson LC, Oude Luttikhuis ME, Baraitser M, et al. Normal erythrocyte membrane Gs-alpha bioactivity in two unrelated patients with acrodysostosis. J Med Genet 1997; 34: 133–6.
44. Graham JM, Krakow D, Tolo VT, et al. Radiographic findings and Gs-alpha bioactivity studies and mutation screening in acrodysostosis indicate a different etiology from pseudohypoparathyroidism. Pediatr Radiol 2001; 31: 2–9.
45. Ellis NA, Groden J, Ye TZ, et al. The Bloom syndrome gene product is homologous to RecQ helicases. Cell 1995; 83: 655–66.
46. German J. Bloom syndrome: a Mendelian prototype of somatic mutational disease. Medicine 1993; 72: 393–406.
47. German J. Bloom syndrome: the first 100 cancers gene. Cancer Genet Cytogenet 1997; 93: 100–6.
48. Hickson ID. RecQ helicases: caretakers of the genome. Nat Rev Cancer 2003; 3: 169–78.
49. Chaganti RS, Schonberg S, German J. A manyfold increase in sister chromatid exchanges in Bloom syndrome lymphocytes. Proc Natl Acad Sci USA 1974; 71: 4508–12.
50. Tischkowitz MD, Hodgson SV. Fanconi anaemia. J Med Genet 2003; 40: 1–10.
51. Levitus M, Rooimans MA, Steltenpool J, et al. Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. Blood 2004; 103: 2498–503.
52. Wajnrajch MP, Gertner JM, Huma Z, et al. Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry. Pediatrics 2001; 107: 744–54.
53. Butturini A, Gale RP, Verlander PC, et al. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood 1994; 84: 1650–5.
54. Alter BP. Cancer in Fanconi anemia, 1927–2001. Cancer 2003; 97: 425–40.
55. Krantz ID, McCallum J, DeScipio C, et al. Cornelia de Lange syndrome is caused by mutations in NIPBL, the human homolog of Drosophila melanogaster Nipped-B. Nat Genet 2004; 36: 631–5.
56. Tonkin ET, Wang TJ, Lisgo S, et al. NIPBL, encoding a homolog of fungal Scc2-type sister chromatid cohesion proteins and fly Nipped-B, is mutated in Cornelia de Lange syndrome. Nat Genet 2004; 36: 636–41.
57. Musio A, Selicorni A, Focarelli ML, et al. X-linked Cornelia de Lange syndrome owing to SMC1L1 mutations. Nat Genet 2006; 38: 528–30.
58. Deardorff MA, Kaur M, Yaeger D, et al. Mutations in cohesin complex members SMC3 and SMC1A cause a mild variant of Cornelia de Lange syndrome with predominant mental retardation. Am J Hum Genet 2007; 80: 485–94.
59. Jackson L, Kline AD, Barr MA, Koch S. de Lange syndrome: a clinical review of 310 individuals. Am J Med Genet 1993; 47: 940–6.
60. Ireland M, Donnai D, Burn J. Brachmann–de Lange syndrome. Delineation of the clinical phenotype. Am J Med Genet 1993; 47: 959–64.
61. Butler MG, Dahir GA, Gale DD, Meaney FJ. Metacarpophalangeal pattern profile analysis in Brachmann–de Lange syndrome. Am J Med Genet 1993; 47: 1003–5.
62. Kline AD, Barr M, Jackson LG. Growth manifestations in the Brachmann–de Lange syndrome. Am J Med Genet 1993; 47: 1042–9.
63. Kline AD, Stanley C, Belevich J, et al. Developmental data on individuals with the Brachmann–de Lange syndrome. Am J Med Genet 1993; 47: 1053–8.
64. Holder SE, Grimsley LM, Palmer RW, et al. Partial trisomy 3q causing mild Cornelia de Lange phenotype. J Med Genet 1994; 31: 150–2.
65. Goodship J, Gill H, Carter J, et al. Autozygosity mapping of a Seckel syndrome locus to chromosome 3q22.1-q24. Am J Hum Genet 2000; 67: 498–503.
66. Børglum AD, Balslev T, Haagerup A, et al. A new locus for Seckel syndrome on chromosome 18p11.31-q11.2. Eur J Hum Genet 2001; 9: 753–57.
67. Kilinç MO, Ninis VN, Ugur SA, et al. Is the novel SCKL3 at 14q23 the predominant Seckel locus. Eur J Hum Genet 2003; 11: 851–57.
68. O’Driscoll M, Ruiz-Perez VL, Woods CG, et al. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 2003; 33: 497–501.
69. Casper AM, Durkin SG, Arlt MF, Glover TW. Chromosomal instability at common fragile sites in Seckel syndrome. Am J Hum Genet 2004; 75: 654–60.
70. Spranger JW, Brill PW, Poznanski A, eds. Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development. Oxford: University Press, 2002.
71. Hall JG, Flora C, Scott CI, et al. Majewski osteodysplastic primordial dwarfism type II: natural history and clinical findings. Am J Med Genet 2004; 130A: 55–72.
72. Winter RM. Dubowitz syndrome. In: Donnai D, Winter RM, eds. Congenital Malformation Syndromes. London: Chapman & Hall Medical, 1995: 133–6.
73. Tsukahara M, Opitz JM. Dubowitz syndrome: review of 141 cases including 36 previously unreported patients. Am J Med Genet 1996; 63: 277–89.
74. Hansen KE, Kirkpatrick SJ, Laxova R. Dubowitz syndrome: long-term follow-up of an original patient. Am J Med Genet 1995; 55: 161–4.
75. Price SM, Stanhope R, Garrett C, et al. The spectrum of Silver–Russell syndrome: a clinical and molecular genetic study and new diagnostic criteria. J Med Genet 1999; 36: 837–42.
76. Wollmann HA, Kirchner T, Enders H, et al. Growth and symptoms in Silver–Russell syndrome: review on the basis of 386 patients. Eur J Pediatr 1995; 154: 958–68.
77. Saal HM, Pagon RA, Pepin MG. Reevaluation of Russell–Silver syndrome. J Pediatr 1985; 107: 733–7.
78. Lai KY, Skuse D, Stanhope R, Hindmarsh P. Cognitive abilities associated with the Silver–Russell syndrome. Arch Dis Child 1994; 71: 490–6.
79. Anderson J, Viskochil D, O’Gorman M, Gonzales C. Gastrointestinal complications of Russell–Silver syndrome: a pilot study. Am J Med Genet 2002; 113: 15–9.
80. Hitchins MP, Stanier P, Preece MA, Moore GE. Silver–Russell syndrome: a dissection of the genetic aetiology and candidate chromosomal regions. J Med Genet 2001; 38: 810–9.
81. Kotzot D, Balmer D, Baumer A, et al. Maternal uniparental disomy 7 – review and further delineation of the phenotype. Eur J Pediatr 2000; 159: 247–56.
82. Charalambous M, Smith FM, Bennett WR, et al. Disruption of the imprinted Grb10 gene leads to disproportionate overgrowth by an Igf2-independent mechanism. Proc Natl Acad Sci USA 2003; 100: 8292–7.
83. Midro AT, Debek K, Sawicka A, et al. Second observation of Silver–Russell syndrome in a carrier of a reciprocal translocation with one breakpoint at site 17q25. Clin Genet 1993; 44: 53–5.
84. Escobar V, Gleiser S, Weaver DD. Phenotypic and genetic analysis of the Silver–Russell syndrome. Clin Genet 1978; 13: 278–88.
85. Duncan PA, Hall JG, Shapiro LR, Vibert BK. Threegeneration dominant transmission of the Silver–Russell syndrome. Am J Med Genet 1990; 35: 245–50.
86. Hennekam RC, Bijlsma JB, Spranger J. Further delineation of the 3-M syndrome with review of the literature. Am J Med Genet 1987; 28: 195–209.
87. Flannery DB. 3-M syndrome. Am J Med Genet 1989; 32: 252–4.
88. van der Wal G, Otten BJ, Brunner HG, van der Burgt I. 3-M syndrome: description of six new patients with review of the literature. Clin Dysmorphol 2001; 10: 241–52.
89. Elliott AM, Graham JM, Curry CJ, et al. Spectrum of dolichospondylic dysplasia: two new patients with distinctive findings. Am J Med Genet 2002; 113: 351–61.
90. Pelletier G, Feingold M. Case report 1. In: Bergsma D, ed. Syndrome Identification, Vol 1. New York: White Plains, National Foundation – March of Dimes, 1973: 8–9.
91. Leisti J, Hollister DW, Rimoin DL. Case report 2. In: Bergsma D, ed. Syndrome Identification, Vol 2. New York: White Plains, National Foundation – March of Dimes, 1974: 305.
92. Houlston RS, Collins AL, Dennis NR, Temple IK. Further observation on the Floating–Harbor syndrome. Clin Dysmorphol 1994; 3: 143–9.
93. Wieczorek D, Wüsthof A, Harms E, Meinecke P. Floating–Harbor syndrome in two unrelated girls: mild short stature in one patient and effective growth hormone therapy in the other. Am J Med Genet 2001; 104: 47–52.
94. Patton MA, Hurst J, Donnai D, et al. Floating–Harbor syndrome. J Med Genet 1991; 28: 201–4.
95. Ala-Mello S, Peippo M. The first Finnish patient with the Floating–Harbor syndrome: follow-up of eight years. Am J Med Genet 2004; 130A: 317–9.
96. Perheentupa J, Autio S, Leisti S, et al. Mulibrey nanism, an autosomal recessive syndrome with pericardial constriction. Lancet 1973; 2: 351–5.
97. Karlberg N, Jalanko H, Perheentupa J, Lipsanen-Nyman M. Mulibrey nanism: clinical features and diagnostic criteria. J Med Genet 2004; 41: 92–8.
98. Avela K, Lipsanen-Nyman M, Idänheimo N, et al. Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism. Nat Genet 2000; 25: 298–301.
99. Hamalainen RH, Avela K, Lambert JA, et al. Novel mutations in the TRIM37 gene in mulibrey nanism. Hum Mutat 2004; 23: 522.
100. Kallijärvi J, Avela K, Lipsanen-Nyman M, et al. The TRIM37 gene encodes a peroxisomal RING-B-Box- Coiled-Coil protein: classification of mulibrey nanism as a new peroxisomal disorder. Am J Hum Genet 2002; 70: 1215–28.
101. Raitta C, Perheentupa J. Mulibrey nanism: an inherited dysmorphic syndrome with characteristic ocular findings. Acta Ophthalmol Suppl 1974; 123: 162–71.
102. Koenig R, Brendel L, Fuchs S. SHORT syndrome. Clin Dysmorphol 2003; 12: 45–49.
103. Haan E, Morris L. SHORT syndrome: distinctive radiographic features. Clin Dysmorphol 1998; 7: 103–7.
104. Toriello HV. Wiedemann-Rautenstrauch syndrome. In: Donnai D, Winter RM, eds. Congenital Malformation Syndromes. London: Chapman & Hall Medical, 1995: 137–40.
105. Pivnick EK, Angle B, Kaufman RA, et al. Neonatal progeroid (Wiedemann–Rautenstrauch) syndrome: report of five new cases and review. Am J Med Genet 2000; 90: 131–40.
106. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP- 2, cause Noonan syndrome. Nat Genet 2001; 29: 465–8.
107. Roberts AE, Araki T, Swanson KD, et al. Germline gain-offunction mutations in SOS1 cause Noonan syndrome. Nat Genet 2007; 39: 70–4.
108. Allanson JE, Hall JG, Hughes HE, et al. Noonan syndrome: the changing phenotype. Am J Med Genet 1985; 21: 507–14.
109. Allanson JE. Noonan syndrome. In: Cassidy SB, Allanson JE, eds. Management of Genetic Syndromes. New York: Wiley-Liss, 2001: 253–68.
110. Noonan JA, Raaijmakers R, Hall BD. Adult height in Noonan syndrome. Am J Med Genet 2003; 123: 68–71.
111. Witt DR, Keena BA, Hall JG, Allanson JE. Growth curves for height in Noonan syndrome. Clin Genet 1986; 30: 150–3.
112. Kirk JM, Betts PR, Butler GE, et al. Short stature in Noonan syndrome: response to growth hormone therapy. Arch Dis Child 2001; 84: 440–3.
113. Noordam C, van der Burgt I, Sengers RC, et al. Growth hormone treatment in children with Noonan syndrome: four year results of a partially controlled trial. Acta Paediatr 2001; 90: 889–94.
114. van der Burgt I, Thoonen G, Roosenboom N, et al. Patterns of cognitive functioning in school-aged children with Noonan syndrome associated with variability in phenotypic expression. J Pediatr 1999; 135: 707–13.
115. Keren B, Hadchouel A, Saba S, et al. PTPN11 mutations in patients with LEOPARD syndrome: French multicentric experience. J Med Genet 2004; 41: e117.
116. Gelb BD, Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kihase signal transduction. Human Molec Genet 2006; 15: R220–6.
117. Hall BD. Choanal atresia and associated multiple anomalies. J Pediatr 1979; 95: 395–8.
118. Hittner HM, Hirsch NJ, Kreh GM, Rudolph AJ. Colobomatous microphthalmia, heart disease, hearing loss and mental retardation: a syndrome. J Pediatr Ophthalmol Strabismus 1979; 16: 122–8.
119. Amiel J, Attie-Bitach T, Marianowski R, et al. Temporal bone anomaly proposed as a major criteria for diagnosis of CHARGE syndrome. Am J Med Genet 2001; 99: 124–7.
120. Graham JM Jr. Editorial comment: A recognizable syndrome within CHARGE association: Hall–Hittner syndrome. Am J Med Genet 2001; 99: 120–3.
121. Oley CA. CHARGE association. In: Cassidy SB, Allanson JE, eds. Management of Genetic Syndromes. New York: Wiley-Liss, 2001: 71–84.
122. Tellier AL, Cormier-Daire V, Abadle V, et al. CHARGE syndrome: report of 47 cases and review. Am J Med Genet 1998; 76: 402–9.
123. Vissers LE, van Ravenswaaij CM, Admiraal R, et al. Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nature Genet 2004; 36: 955–7.
124. Smithson SF, Thompson EM, McKinnon AG, et al. The KBG syndrome. Clin Dysmorphol 2000; 9: 87–91.
125. Herrmann J, Pallister PD, Tiddy W, et al. The KBG syndrome – a syndrome of short stature, characteristic facies, mental retardation, macrodontia and skeletal anomalies. BDOAS 1975; 11: 7–18.
126. Dowling PA, Fleming P, Gorlin RJ, et al. The KBG syndrome, characteristic dental findings: a case report. Int J Paediatr Dent 2001; 11: 131–4.
127. Tekin M, Kavaz A, Berberoglu M, et al. The KBG syndrome: confirmation of autosomal dominant inheritance and further delineation of the phenotype. Am J Med Genet 2004; 130A: 284–7.
128. Petrij F, Dauwerse HG, Blough RI, et al. Diagnostic analysis of the Rubinstein–Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations. J Med Genet 2000; 37: 168–76.
129. Petrij F, Giles RH, Dauwerse HG, et al. Rubinstein–Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995; 376: 348–51.
130. Allanson JE. Microcephaly in Rubinstein–Taybi syndrome. Am J Med Genet 1993; 46: 244–6.
131. Stevens CA, Hennekam RCM, Blackburn BL. Growth in the Rubinstein–Taybi syndrome. Am J Med Genet 1990; 37(Suppl 6): 51–55.
132. Stevens C, Bhakta M. Cardiac abnormalities in the Rubinstein–Taybi syndrome. Am J Med Genet 1995; 59d: 346–8.
133. Rubinstein J. Broad thumb-hallux (Rubinstein–Taybi) syndrome 1957–1988. Am J Med Genet 1990; 37(Suppl 6): 3–16.
134. Hennekam RCM, Van Den Boogaard MJ, Sibbles BJ, Van Spijker HG. Rubinstein–Taybi syndrome in the Netherlands. Am J Med Genet 1990; 37(Suppl 6): 17–29.
135. Stevens CA, Carey JC, Blackburn BL. Rubinstein–Taybi syndrome: a natural history study. Am J Med Genet 1990; 37(Suppl 6): 30–7.
136. Wiley S, Swayne S, Rubinstein JH, et al. Rubinstein–Taybi syndrome medical guidelines. Am J Med Genet 2003; 119A: 101–10.
137. Kuroki Y, Suzuki Y, Chyo H, et al. A new malformation syndrome of long palpebral fissures, large ears, depressed nasal tip and skeletal anomalies associated with postnatal dwarfism and mental retardation. J Pediatr 1981; 99: 570–3.
138. Niikawa N, Matsuura N, Fukushima, et al. Kabuki makeup syndrome: a syndrome of mental retardation, unusual facies, large and protruding ears, and postnatal growth deficiency. J Pediatr 1981; 99: 565–9.
139. Armstrong L, El Moneim AA, Aleck K, et al. Further delineation of Kabuki syndrome in 48 well-defined new individuals. Am J Med Genet 2004; 132A: 265–72.
140. Nance MA, Berry SA. Cockayne syndrome: review of 140 cases. Am J Med Genet 1992; 42: 68–84.
141. Boltshauser E, Yalcinkaya C, Wichmann W, et al. MRI in Cockayne syndrome type I. Neuroradiology 1989; 31: 276–7.
142. Dollfus H, Porto F, Caussade P, et al. Ocular manifestations in the inherited DNA repair disorders. Surv Ophthalmol 2003; 48: 107–22.
143. Mayne LV, Lehmann AR. Failure of RNA synthesis to recover after UV-irradiation: an early defect in cells from individuals with Cockayne syndrome and xeroderma pigmentosa. Cancer Res 1982; 42: 1473–8.
144. Van Gool AJ, Citterio E, Rademakers S, et al. The Cockayne syndrome B protein, involved in transcriptioncoupled DNA repair, resides in an RNA polymerase II-containing complex. EMBO J 1997; 16: 5955–65.
145. Rapin I, Lindenbaum Y, Dickson DW, et al. Cockayne syndrome and xeroderma pigmentosum. Neurology 2000; 55: 1442–9.
146. Meira LB, Graham JM Jr., Greenberg CR, et al. Manitoba aboriginal kindred with original cerebro-oculo-facioskeletal syndrome has a mutation in the Cockayne syndrome group B gene. Am J Hum Genet 2000; 66: 1221–8.
147. Brown WT. Progeria: a human disease model of accelerated ageing. Am J Clin Nutr 1992; 55: 1222S–1224S.
148. Pollex RL, Hegele RA. Hutchinson–Gilford progeria syndrome. Clin Genet 2004; 66: 375–81.
149. Baker PB, Baba N, Boesel CP. Cardiovascular abnormalities in progeria. Case report and review of the literature. Arch Pathol Lab Med 1981; 105: 384–6.
150. De Sandre-Giovannoli A, Bernard R, Cau P, et al. Lamin A truncation in Hutchinson–Gilford progeria. Science 2003; 300: 2055.
151. Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome. Nature 2003; 423: 293–8.
152. Worman HJ. Nuclear envelope proteins and human disease. In: Evans DE, Hutchinson CJ, Bryant JA, eds. The Nuclear Envelope. New York: BIOS Scientific Publishers, 2004: 41–56.